[Correlation between serum adiponectin level and cognitive function in patients with Alzheimer's disease]

Area of Science:

• Neuroscience
• Biochemistry
• Gerontology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment.
• Adiponectin, an adipokine, has been implicated in various physiological processes, including inflammation and metabolism, with potential roles in neurological conditions.

Purpose of the Study:

• To examine serum adiponectin levels in individuals diagnosed with Alzheimer's disease.
• To assess the relationship between serum adiponectin concentrations and the severity of cognitive dysfunction in AD patients.

Main Methods:

• A case-control study involving 90 Alzheimer's disease patients, categorized by Mini-Mental State Examination (MMSE) scores into mild, moderate, and severe groups.
• A control group of 90 healthy individuals, matched for age and gender.
• Serum adiponectin quantification using enzyme-linked immunosorbent assay (ELISA).

Main Results:

• Serum adiponectin levels were significantly diminished in the overall Alzheimer's disease group compared to the healthy control group (P<0.05).
• Patients with moderate and severe AD exhibited significantly lower serum adiponectin levels than controls (P<0.05), while the mild AD group did not show a significant difference (P>0.05).
• A significant positive correlation was found between serum adiponectin levels and MMSE scores in AD patients (r=0.683, P<0.001), indicating an association with cognitive function.

Conclusions:

• Reduced serum adiponectin levels are a characteristic finding in Alzheimer's disease patients.
• The degree of cognitive impairment in Alzheimer's disease is associated with lower serum adiponectin concentrations.